Selvigaltin (GB1211), an orally offered small molecule galectin-three inhibitor produced to be a remedy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-3 with GB1211 was not linked to any cure- or dose-similar https://selvigaltin-galectin-3-in91356.csublogs.com/46862891/selvigaltin-an-overview